Search Results for "Lipids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lipids. Results 131 to 140 of 149 total matches.
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
% with
risankizumab 360 mg, and 2.1% with placebo. Lipid
elevations have been reported with the drug. Serious ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab was approved earlier for treatment of
plaque psoriasis and psoriatic arthritis.
Pioglitazone/Metformin (Actoplus met)
The Medical Letter on Drugs and Therapeutics • Jan 30, 2006 (Issue 1227)
of lipid and glycemic effects
of pioglitazone and rosiglitazone in patients with type 2 diabetes ...
For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination (Actoplus met - Takeda) of two widely used antihyperglycemic drugs, the thiazolidinedione pioglitazone (Actos) and the biguanide metformin (Glucophage, and others), has been approved by the FDA for management of type 2 diabetes. It is indicated for patients already being treated with both pioglitazone and metformin or as second-line therapy for those not adequately controlled with either metformin or pioglitazone alone....
Clascoterone Cream (Winlevi) for Acne
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
antagonist that inhibits
production of lipids and inflammatory cytokines from
sebocytes in vitro. J Drugs ...
The FDA has approved Winlevi (Sun), a 1% cream
formulation of the androgen receptor inhibitor
clascoterone, for treatment of acne vulgaris in
patients ≥12 years old. It is the first topical androgen
receptor inhibitor to be approved by the FDA.
Initial Therapy of Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 05, 2004 (Issue 1186)
and an angiotensin-receptor blocker (ARB) have intensified the debate.
ALLHAT — ALLHAT (Antihypertensive and Lipid ...
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Pitavastatin (Livalo) - The Seventh Statin
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010 (Issue 1343)
comparing its efficacy in lowering serum lipid concentrations to that of other drugs in its class ...
The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor
(“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan
since 2003. All of the statins now available in the US are listed in the table on page 58.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
tract infection,
increased blood creatinine phosphokinase, lipid level
increases, rash, acne, headache ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
55.20 bradycardia and lipid changes
Beta-Adrenergic Blockers with Alpha-Blocking Properties
Carvedilol ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Drugs for Thyroid Disorders
Treatment Guidelines from The Medical Letter • Aug 01, 2009 (Issue 84)
differences in multiple
quality-of-life measures (depression, fatigue, etc),
body weight, or lipid ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
supplement
on lipid profile, bone mineral density, and symptoms in
menopausal women: a randomized, double ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
tofacitinib levels and should be avoided.31
monitoring of complete blood counts, lipid levels,
and liver ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.